Combining Postcards, Crisis Cards, and Telephone Contact Into a Decision-Making Algorithm to Reduce Suicide Reattempt: A Randomized Clinical Trial of a Personalized Brief Contact Intervention

Guillaume Vaiva, MD, PhD; Sofian Berrouiguet, MD; Michel Walter, MD, PhD; Philippe Courtet, MD, PhD, PhD; François Ducrocq, MD; Vincent Jardon, MD; Mark E. Larsen, PhD; Lionel Cailhol, MD, PhD; Carole Godesense, MD; Christophe Couturier, MD; Anjali Mathur, MD; Virginie Lagree, MD; Catherine Pichene, MD; David Travers, MD, PhD; Cedric Lemogne, MD, PhD; Jean Marc Henry, MD; Frederic Jover, MD; Francoise Chastang, MD; Olivier Prudhomme, MD; Philippe Lestavel, MD; Catherine Thevenon Gignac, MD; Stéphane Duhem, PhD; Anne Laure Demarty; Catherine Mesmeur; Frank Bellivier, MD, PhD; Julien Labreuche, BST; Alain Duhamel, MD, PhD; and Patrick Goldstein, MD

Published: September 25, 2018

Article Abstract

Background: There is growing evidence in the literature that brief contact interventions (BCIs) might be reliable suicide prevention strategies.

Objective: To assess the effectiveness of a decision-making algorithm for suicide prevention (ALGOS) combining existing BCIs in reducing suicide reattempts in patients discharged after a suicide attempt.

Methods: A randomized, multicenter, controlled, parallel trial was conducted in 23 hospitals. The study was conducted from January 26, 2010, to February 28, 2013. People who had made a suicide attempt were randomly assigned to either the intervention group (ALGOS) or the control group. The primary outcome was the rate of participants who reattempted suicide (fatal or not) within the 6-month study period.

Results: 1,040 patients were recruited. After 6 months, 58 participants in the intervention group (12.8%) reattempted suicide compared with 77 (17.2%) in the control group. The difference between groups (4.4%; 95% CI, −0.7% to 9.0%) was not significant (complete-case analysis, P = .059).

Conclusions: These results may help researchers better integrate BCIs into routine health care and provide new insights concerning personalized suicide prevention strategies.

Trial Registration: ClinicalTrials.gov identifier: NCT01123174

Volume: 79

Quick Links: Depression (MDD) , Suicide

Continue Reading…

Subscribe to read the entire article

$40.00

Buy this Article as a PDF

References

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Original Research

Sublingual Dexmedetomidine for the Treatment of Acute Agitation in Adults With Schizophrenia or Schizoaffective Disorder: A Randomized Placebo-Controlled Trial

This RCT determined whether a single dose of sublingual dexmedetomidine reduced acute agitation associated with schizophrenia or...

Read More...